deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02669017

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Sponsor: ADC Therapeutics S.A.

Conditions Burkitt's Lymphoma Chronic Lymphocytic Leukemia Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse Lymphoma, Mantle-Cell Lymphoma, Marginal Zone Non-Hodgkin Lymphoma Primary Mediastinal B-cell Lymphoma Waldenstrom Macroglobulinemia
Interventions ADCT-402
Updated 20 times since 2017 Last updated: Apr 27, 2021 Started: Mar 31, 2016 Primary completion: Feb 21, 2019 Completion: Feb 21, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Burkitt's Lymphoma and Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by ADC Therapeutics S.A. and has accumulated 20 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Nov 2019 · 10 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE1

▶ Show 15 earlier versions

  1. Jun 2021 — Jan 2022 [monthly]

    Completed PHASE1

  2. Mar 2021 — Jun 2021 [monthly]

    Completed PHASE1

  3. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE1

  4. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

  5. Nov 2019 — May 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  6. Jan 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  9. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  10. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE1

  11. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  12. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  13. May 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  14. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ADC Therapeutics S.A.
Data source: ADC Therapeutics S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations